Cold chain logistics frequently fails because temperature excursions are discovered only after delivery, when corrective action is impossible. Traditional passive loggers and carrier milestone tracking create visibility gaps, particularly during handoffs and customs holds, leaving critical condition data unverified. Tive addresses this challenge through real-time monitoring technology combining multi-sensor hardware with cloud-based visibility platforms that issue alerts during transit rather than after delivery. This proactive approach enables supply chain teams to intervene immediately when temperature deviations occur, build comprehensive compliance documentation, and prevent costly cargo rejections across pharmaceutical, perishables, and life sciences sectors.

As of 2026, most of the temporary FDA exemptions for connected manufacturers, repackagers, wholesale distributors, and larger dispensers have expired.

European Union's Falsified Medicines Directive (FMD) mandates serialization. Counterfeit prevention: Unique identifiers help verify authenticity in real time. ...

Serialization Is No Longer About Compliance—It Is Becoming the Digital Identity of Every Medicine When pharmaceutical serialization was first introduced, ...

The FDA conducted a public meeting on June 15, 2026, to address stakeholder concerns regarding implementation of the Food Traceability Rule, particularly focusing on lot-level tracking and compliance flexibilities. The Food Traceability Final Rule establishes enhanced recordkeeping requirements for entities manufacturing, processing, packing, or holding foods listed on the Food Traceability List. As a cornerstone of the FDA's New Era of Smarter Food Safety Blueprint, this rule implements Section 204(d) of the FDA Food Safety Modernization Act and mandates maintenance of Key Data Elements associated with Critical Tracking Events. The rule requires entities to provide information to the FDA within 24 hours or an agreed timeframe, enabling faster identification and removal of contaminated food from the market, thereby reducing foodborne illness incidents and deaths across the entire farm-to-table supply chain for both domestic and foreign producers.

For many pharmaceutical companies, the conversation around aggregation starts with compliance. But treating it as just another regulatory box to check is a missed opportunity. The real power of aggregation in pharma serialization lies in the operational excellence it unlocks. It’s the key to streamlining your warehouse, enabling surgical-precision product recalls, and building a nearly impenetrable defense against counterfeit drugs. By creating a clear, verifiable link from the unit to the pallet, you gain a level of control and visibility that impacts your bottom line. This guide will explore the powerful business benefits of aggregation that go far beyond compliance, showing you how it can become a true competitive advantage.

Pharmaceutical serialization is the process of assigning unique, machine-readable identifiers to individual medicine packs through 2D DataMatrix barcodes, enabling comprehensive tracking from manufacturer to patient. Mandated across more than 60 countries, serialization combines product codes, serial numbers, batch numbers, and expiry dates to create unit-level traceability and authentication. This regulatory requirement distinguishes itself from commercial serialization systems through its legal enforcement and internationally standardized data governance by GS1. As counterfeit medications reportedly cause approximately one million deaths annually, serialization serves as a critical regulatory safeguard by ensuring every legitimate pack carries a verifiable digital fingerprint, thereby identifying fraudulent products through their absence of proper credentials. Serialization forms the foundational infrastructure for broader pharmaceutical track-and-trace systems essential to supply chain integrity.

Pharmaceutical packaging represents a critical yet often overlooked sector where precision and safety are paramount. Unlike standard packaging, pharmaceutical solutions demand zero tolerance for errors, as misprinted dosages or compromised seals directly impact patient welfare. Selecting an appropriate packaging partner constitutes a consequential strategic decision for pharmaceutical brands rather than a routine procurement matter. This guide examines leading pharmaceutical packaging companies across the United States, with particular emphasis on Platinum Press, a Fort Worth-based firm that has established itself as a trusted single-source provider. Operating dual facilities in Texas and New Jersey, Platinum Press offers comprehensive solutions spanning labels, cartons, leaflets, flexible packaging, and foil lidding. The company's recent $15 million expansion demonstrates its commitment to advanced manufacturing capabilities and quality standards essential for serving the pharmaceutical industry's stringent requirements.

The analysis focuses on six conditions: Digital Trade Readiness (DTR), Blockchain-enabled Traceability (BCT), Product Risk (PRK), Market Strictness (MKT), ...

Box label applicators are critical for production efficiency, as mislabeled or unlabeled products result in chargebacks, audit failures, and costly rework. Modern labeling automation employs four primary technologies—wipe-on, tamp-blow, air-blow, and print-and-apply systems—each suited to different production requirements and packaging formats. Servo-driven systems achieve precision placement within ±1mm, while label verification sensors detect missing labels automatically. Operations teams evaluating labeling equipment must understand realistic performance benchmarks, maintenance needs, and integration capabilities with existing packaging lines to maximize overall equipment effectiveness and ensure accurate, seamless production workflows.

What Role Does RFID Play in Pharmaceutical Logistics? Radio frequency identification uses tags and readers to identify products without requiring a direct line ...

Pharma supply chains carry a less visible but equally important advantage. Drug traceability mandates have required the pharmaceutical industry to serialize ...

Pharmaceutical serialization assigns unique identifiers to individual medicine packages, encoded as 2D DataMatrix codes containing serial numbers, product IDs, batch numbers, and expiration dates. This system enables end-to-end tracking from manufacturer to patient and serves as the primary defense against counterfeit drugs, which cost the global industry an estimated $200 billion annually. Serialization satisfies regulatory requirements such as DSCSA and EU FMD while ensuring supply chain transparency. Each identifier allows precise identification of affected units during quality issues without recalling entire product lines. The four core data elements—GTIN, serial number, batch number, and expiration date—create a reliable mechanism to distinguish genuine products from counterfeits and eliminate supply chain blind spots.

This article examines manufacturing execution systems for the pharmaceutical industry, comparing platforms such as PAS-X, Tulip, and MasterControl. Adrien Laurent, founder of IntuitionLabs, draws on over 25 years of enterprise software experience to guide organizations through MES selection challenges. The discussion addresses the complexities of implementing Electronic Batch Records and manufacturing solutions tailored to life science requirements. IntuitionLabs specializes in custom AI solutions for pharmaceutical and life science companies seeking to optimize their operational processes. The content is intended for educational purposes and emphasizes the importance of independent verification before implementation decisions.

Pharmaceutical leaders face mounting regulatory pressure to implement AI governance frameworks, with the EU AI Act's strictest requirements taking effect in August 2026. Rather than applying uniform oversight to all models, industry best practice demands proportionate risk assessment. This article presents a structured seven-category checklist enabling pharma organizations to evaluate AI models consistently and defensibly. The framework integrates with existing ICH Q9 quality risk management standards and enterprise risk management programs, enabling quality units, IT security, privacy, and business stakeholders to align on governance decisions without repetitive principle-based debates. The approach prioritizes appropriate scrutiny levels based on actual risk, preventing both dangerous under-oversight of high-risk systems and inefficient over-documentation of low-risk applications.

Several major soda brands will add QR codes linking consumers to detailed ingredient information on their cans and bottles in an effort to provide "greater transparency." The American Beverage Association, a trade group representing hundreds of producers and distributors, said it would expand an ongoing digital initiative over the next two years. The QR codes will take customers to a database built by the association that lists information on over 140 ingredients. The Coca-Cola Company, Keurig Dr Pepper and PepsiCo have all signed onto the project.

Healthcare systems are overlooking a critical artificial intelligence application in pharmacy inventory management, despite its significant impact on operational efficiency and patient care. Drug shortages cost U.S. hospitals approximately $900 million annually and consume 20 million labor hours, diverting skilled pharmacists from direct patient care. The root cause lies in fragmented, outdated systems that lack real-time visibility across multiple pharmacy locations managing thousands of drug SKUs with complex regulatory requirements. Most healthcare organizations operate with manual processes, disconnected software, and institutional knowledge rather than integrated technology solutions. The absence of system-wide integration between electronic medical records, enterprise resource planning systems, and pharmacy supply chains forces reactive problem-solving through spreadsheets and manual communications. Implementing AI-driven inventory management represents an underutilized opportunity to streamline operations, reduce costs, and reallocate pharmacist expertise toward patient-focused clinical services.

Strides Pharma Inc., a Bridgewater-based pharmaceutical company, initiated a nationwide voluntary recall of approximately 90,000 bottles of Children's Ibuprofen Oral Suspension following consumer complaints about foreign contamination. The affected product, manufactured for Taro Pharmaceuticals USA and produced in India, contained gel-like masses and black particles. The recall encompasses lot numbers 7261973A and 7261974A, both expiring January 31, 2027. Consumers are advised to verify lot numbers and expiration dates on their product packaging against the official recall notice to identify affected bottles.

Pharmaceutical companies must distinguish between serialization and aggregation to achieve FDA compliance under DSCSA requirements. Serialization assigns unique identifiers to individual drug units through 2D barcodes, answering what a product is. Aggregation establishes parent-child relationships between serialized units and their outer packaging levels—cases, shippers, and pallets—answering where products are located and their transportation companions. While many operations implement serialization effectively, aggregation remains widely misunderstood and poorly executed. FDA inspectors recognize this gap: facilities printing barcodes without real-time visibility into which cartons occupy specific cases and pallets lack true compliance. Both processes are mandatory under DSCSA and GS1 standards. Proper implementation requires integrated systems that verify serialization at line level and maintain complete aggregation data accessible throughout the supply chain, ensuring regulatory adherence and product traceability.

Drug recalls are surprisingly common – over 14,000 recalls in the last decade in the U.S. alone – and they can be triggered by many factors. The most frequent causes include contamination and sterility failures, cGMP and manufacturing violations, labeling/packaging errors, incorrect potency (OOS), and unexpected safety issues. These recalls range from minor fixes (Class III) to life-threatening hazards (Class I). We’ll explore each top cause, real-world examples, and essential prevention steps – from implementing robust quality systems (QMS/CAPA) to using automated inspection and packaging validation. Throughout, we emphasize how advanced packaging machinery and inspection technology (like Jinlu Packing’s solutions) can dramatically reduce recall risk.